Quick FactsIt is projected that as many as 70 million people could die of tuberculosis over the next 3 decades.
The Company's long-term vision is to radically improve treatment of a variety of infectious diseases with efficacious new and safe antibiotics that each have a novel mechanism of action.
Our small molecule product candidates act on multiple and different cellular pathways and have broad market potential, with applications in pulmonary infections, GI infections, fungal infections, and parasitic diseases. Our current antibiotic pipeline includes lead drug candidates and back-up compounds that address serious, life-threatening infectious diseases such as tuberculosis, Helicobacter pylori gastrointestinal infection (linked to gastric ulcers and cancer), Clostridium difficile infection (the etiologic agent that causes pseudomembraneous colitis), nontubercular mycobacterial diseases (linked to pneumonias and Crohn's Disease), and fungal and parasitic infections.
Sequella develops novel small molecule and natural product-based therapeutics for a variety of infectious diseases. Our Drug Discovery Programs identify new scaffolds with antibacterial and antifungal activity, and we create 10,000 to 70,000 compound libraries around each active scaffold using focused solid-phase and solution-phase combinatorial chemistry.
Sequella scientists developed and validated several high-throughput screening assays that are used to analyze the libraries for target pathogen activity and identify the most promising compounds for clinical development.
Discovery and lead optimization are conducted at our Rockville headquarters, which houses chemistry, cell biology, and microbiology laboratories, as well as Biosafety Level-3 (BSL-3) laboratories for the manipulation of high-hazard pathogenic microorganisms. This infrastructure, combined with our established methods and expertise, expedite the lead compound identification process.